Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2007

Sartorius Stedim Biotech and Greenovation Partner on Process-Scale Application of Moss-Based Protein Production Platform

  • Sartorius Stedim Biotech and greenovation Biotech will work on the process-scale implementation of the latter’s technology for producing complex proteins from moss cells called bryotechnology.

    The companies have been working together to develop fermentation processes in the field of bryotechnology. Yet, notes Hans-Peter Casel, managing director of Sartorius Stedim Systems, “The special requirements of the GMP environment pose real challenges to process-scale implementation of bryotechnology.”

    Sartorius Stedim Biotech says that it will now work on delivering the first GMP-compliant photobioreactor for bryotechnological applications within the next few months.

    Bryotechnology simplifies the process engineering involved with drug manufacturing, according to the firms.  Moss cells can be cultivated using relatively simple culture medium compositions, which reduce the complexity involved in controlling the process, they explain.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »